<DOC>
	<DOCNO>NCT01662791</DOCNO>
	<brief_summary>The potential role small bowel bacterial overgrowth ( SBBO ) weight loss occur patient Parkinson 's Disease ( PD ) previously examine . Our hypothesis SBBO important contributor development weight loss individual PD . The investigator propose 1 ) examine role SBBO weight loss occur patient PD 2 ) determine response treatment poorly absorb antibiotic . The investigator perform prospective , observational case-control study ( Part 1 ) open-label therapeutic component ( Part 2 ) . Cases define PD patient experience significant weight loss Controls define PD patient experience significant weight loss .</brief_summary>
	<brief_title>Weight Loss Parkinson 's Disease Role Small Bowel Bacterial Overgrowth</brief_title>
	<detailed_description>Part 1 : Consecutive patient see Parkinson 's disease clinic Mayo Clinic Arizona approach participate . After determination eligibility appropriate sign informed consent , PD patient ( i.e. , Case Control group ) underwent follow : 1 . Assessment demographic feature , weight history PD history 2 . PD medication 3 . Determination PD severity use Unified Parkinson 's Disease rating scale 4 . Gastrointestinal Symptom Severity Index ( GISSI ) modify GISSI . 5 . Determination usual calorie nutrient intake ( Brief Block Food Frequency Questionnaire ) 6 . Paffenbarger physical activity questionnaire 7 . Quality life ( SF12 PD-specific ) 8 . Hospital Anxiety Depression Scale 9 . Glucose hydrogen breath test ( SBBO test ) 10 . Qualitative assessment smell taste All questionnaire complete 2 hour breath test . Part 2 : All individual weight loss group ( i.e. , Case group ) offer open-label treatment poorly absorb antibiotic , rifaximin , 550 mg PO twice day 14 day . Treatment depend upon result bacterial overgrowth breath test . Thus , normal abnormal breath test subject could receive antibiotic treatment . The patient contact phone 1 month treatment time presence GI symptom determine inquiry make adverse effect relate rifaximin use . GI symptom , quality life , weight measurement , breath test repeat 3 month study visit .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Inclusion criterion : Parkinson 's Disease 1 . Wheelchairbound , akinetic individual 2 . Tubefed individual 3 . Presence dementia 4 . Unwilling unable complete test 5 . Allergic intolerant rifaximin 6 . Presence chronic upper low gastrointestinal disorder symptom may confuse SBBO ( e.g. , irritable bowel syndrome , inflammatory bowel disease , celiac disease , functional dyspepsia , gastroparesis , chronic pancreatitis ) 7 . Presence prior surgery gastrointestinal tract except cholecystectomy , appendectomy herniorrhaphy 8 . Presence severe concomitant acute chronic medical condition may interfere completion interpretation test result 9 . Women childbearing potential . Given age patient Parkinson 's disease , anticipate large population . 10 . Use antibiotic within 1 month breath test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Small Bowel Bacterial Overgrowth</keyword>
	<keyword>Weight Loss</keyword>
	<keyword>Gastrointestinal</keyword>
	<keyword>Rifaximin</keyword>
</DOC>